Vol. 2 No. 11 (2022)
Health Technology Reviews

Octreotide Long-Acting Release and Everolimus for Recurrent Meningiomas

Published November 22, 2022

Key Messages

  • The systematic search resulted in 1 single-arm prospective study and 1 retrospective cohort study. No relevant randomized controlled trials, systematic reviews, or evidence-based guidelines were identified that met the criteria for this review.
  • Evidence was limited, inconsistent, and of low quality for the clinical effectiveness of octreotide long-acting release in combination with everolimus in patients with recurrent meningiomas.
  • The quantity and quality of current publications were not sufficient to draw a conclusion in support of or against the clinical effectiveness of octreotide long-acting release in combination with everolimus relative to other systematic therapies in patients with recurrent meningiomas.
  • Additional research is required to inform decision-making in this context.